0001104659-24-083980.txt : 20240730 0001104659-24-083980.hdr.sgml : 20240730 20240730162326 ACCESSION NUMBER: 0001104659-24-083980 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240730 DATE AS OF CHANGE: 20240730 EFFECTIVENESS DATE: 20240730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-520127 FILM NUMBER: 241157805 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 D 1 primary_doc.xml X0708 D LIVE 0001017491 SEELOS THERAPEUTICS, INC. 300 PARK AVENUE 2ND FLOOR NEW YORK NY NEW YORK 10022 (646) 293-2100 NEVADA None APRICUS BIOSCIENCES, INC. NEXMED INC Corporation true Raj Mehra c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Executive Officer Chief Executive Officer Brian Lian c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Richard W. Pascoe c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Margaret Dalesandro c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Michael Golembiewski c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Executive Officer Chief Financial Officer Biotechnology No Revenues 06b false 2024-07-11 false true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue 4th Floor NEW YORK NY NEW YORK 10022 NJ NEW JERSEY NY NEW YORK false 1146481 0 1146481 The total offering amount reflects the total gross proceeds to be received by the company assuming cash exercise of all warrants issued to the accredited investors in the private placements under Rule 506(b). false 3 48725 0 In connection with the offering, the placement agent received $48,725, and warrants to purchase up to 65,782 shares of common stock exercisable at $0.7625 per share, among other items. 0 false SEELOS THERAPEUTICS, INC. /s/ Michael Golembiewski Michael Golembiewski Chief Financial Officer 2024-07-30